这一医疗器械在美国高度垄断，“瓣膜之王”收购遇阻！中国市场百花齐放

Core Insights - The heart valve market is characterized by high research and development barriers, making it a highly competitive sector dominated by leading companies [1][4] - The Federal Trade Commission (FTC) blocked the acquisition of JenaValve Technology by Edwards Lifesciences, citing concerns over reduced competition in the heart valve treatment market [1] - Edwards Lifesciences has indicated it will not pursue the acquisition further but disagrees with the FTC's stance [3] Company Developments - In 2024, Edwards Lifesciences secured multiple heart valve products, including the acquisition of JenaValve, which was previously blocked by the FTC [3] - JenaValve's Trilogy product, a key asset in the acquisition, has received European regulatory approval and is awaiting FDA approval in the U.S. [3] - Edwards Lifesciences' TAVR products have generated significant revenue, with annual sales expected to exceed $4 billion, and approximately $1.15 billion in sales reported for Q3 2025 [3] Market Trends - The heart valve market is increasingly dominated by major players, with Boston Scientific announcing its exit from the heart valve business due to regulatory challenges [4] - In China, over 10 TAVR products have been approved, with local products expected to capture around 80% of the domestic market share [4] - The competitive landscape in the TAVR sector is intensifying, with numerous companies developing related systems [4]